Sana Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.99%. The profit margin, also known as the revenue ratio or gross profit ratio ...

Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are ...

Maxim lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $3 from $5 and keeps a Buy rating on the shares. Sana ...

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.

On Dec. 19, Mesoblast announced the U.S. Food and Drug Administration (FDA) approved Ryoncil. Ryoncil is the first FDA ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...

National American University Holdings Inc (NAUH) is expected to report for 2Q. Neogen Corp (NEOG) is expected to report $-0.01 for 2Q. NexImmune Inc (NEXI) is expected to report for 3Q.

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.